Drug Trial Radar · NCT07129759
Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency
Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Feb 2027
Primary completion
Feb 2030
Study completion Feb 2030
Sponsor
- Lead sponsor
- Lumos PharmaIndustry
- Sponsor type
- Industry
- First posted
- Aug 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Multi-national Trial. The Goal of the Trial is to Offer Subjects Who Complete 12 Months in the LUM-201-10 Phase 3 Trial up to an Additional 36 Months of Treatment of LUM-201 While Evaluating Safety and Tolerability of LUM-201.
Conditions
- Growth Hormone Deficiency (GHD)
Interventions
LUM-201Drug
1.6 mg/kg/day, administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the long-term safety and tolerability of LUM-201Time frame: Day 1 - Month 36
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.